Replimune Group, Inc. - Common Stock (REPL)
8.1000
-0.8400 (-9.40%)
NASDAQ · Last Trade: Oct 21st, 5:50 PM EDT
Detailed Quote
Previous Close | 8.940 |
---|---|
Open | 9.000 |
Bid | 8.020 |
Ask | 8.050 |
Day's Range | 8.060 - 9.450 |
52 Week Range | 2.685 - 17.00 |
Volume | 9,622,982 |
Market Cap | 378.86M |
PE Ratio (TTM) | -2.500 |
EPS (TTM) | -3.2 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 8,605,346 |
Chart
About Replimune Group, Inc. - Common Stock (REPL)
Replimune Group Inc is a biotechnology company focused on developing innovative therapies for cancer treatment using its proprietary oncolytic virus platform. By harnessing genetically engineered viruses that selectively target and destroy cancer cells while stimulating the body’s immune system, Replimune aims to revolutionize the approach to cancer care. The company's research and development efforts are centered on creating novel therapeutic options that can potentially provide more effective and less toxic alternatives to traditional cancer treatments. Through their commitment to scientific advancement, Replimune is poised to make significant contributions to the field of oncology. Read More
News & Press Releases
An investigational treatment, used in combination with another cancer medication, took an important step forward after several setbacks.
Via The Motley Fool · October 20, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Via Chartmill · October 20, 2025
Via Benzinga · October 20, 2025
Let's dive into the action on the US markets on Monday. Here are the most active stocks that are driving the market today.
Via Chartmill · October 20, 2025
What Is Driving Replimune Stock’s 98% Surge Today?stocktwits.com
Via Stocktwits · October 20, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · October 20, 2025
Shares of Replimune Group are rising Monday after the clinical stage biotechnology company shared an important regulatory update.
Via Benzinga · October 20, 2025
Today's session on Monday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · October 20, 2025
Via Benzinga · October 20, 2025
Via Benzinga · October 20, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · October 20, 2025
Via Benzinga · October 20, 2025
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026
By Replimune, Inc. · Via GlobeNewswire · October 20, 2025
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced data from a new ad hoc analysis from the IGNYTE phase 2 cohort of RP1 plus nivolumab was presented by Caroline Robert, M.D., Ph.D., at the European Society for Medical Oncology (ESMO) Congress 2025 being held in Berlin (Poster 1644P).
By Replimune, Inc. · Via GlobeNewswire · October 19, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · October 8, 2025
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) and reminds investors of the September 22, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
By Faruqi & Faruqi, LLP · Via Business Wire · September 22, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · September 22, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · September 22, 2025
NEW YORK - September 22, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit.
Via TheNewswire.com · September 22, 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · September 21, 2025
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 22, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.
By The Rosen Law Firm, P.A. · Via Business Wire · September 20, 2025
The biotech's recent meeting with FDA officials continued to resonate.
Via The Motley Fool · September 19, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · September 19, 2025
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · September 19, 2025
NEW YORK - September 19, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Replimune Group, Inc. (NASDAQ: REPL) of a class action securities lawsuit.
Via TheNewswire.com · September 19, 2025